Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allied BiotechROCO:1780 -1.76%77 Gross Margin % is 37.32% as of Dec. 2025, which is 2% below its 10-year median of 37.98. GuruFocus rates ROCO:1780 with a GF Score™ of 77/100 and a GF Value™ of NT$20.77 (Fairly Valued). The stock has 5 warning signs investors should review. Among 942 Drug Manufacturers companies, Allied Biotech ranks worse than 71.23% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Allied Biotech had a gross margin of 37.32% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Allied Biotech Gross Margin % Related Terms
Allied Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Allied Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allied Biotech Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Allied Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Allied Biotech (ROCO:1780) has a Gross Margin % of 37.32% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Allied Biotech and its competitors. This is near median its historical median of 37.98. Over the past decade, Allied Biotech's Gross Margin % has ranged from 32.02 to 42.91. According to the industry distribution chart, Allied Biotech ranks #671 out of 942 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Allied Biotech's Gross Margin % too high?
Allied Biotech's current Gross Margin % of 37.32% is near median its 10-year median of 37.98. Over the past 10 years, this metric has ranged from a low of 32.02 to a high of 42.91. The Drug Manufacturers industry median Gross Margin % is 48.54. Allied Biotech's value of 37.32% is 23.1% below this industry median. Based on the distribution chart, Allied Biotech ranks #671 out of 942 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Allied Biotech has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allied Biotech ranks #671 out of 942 companies for Gross Margin %. This places Allied Biotech in the lower half of its industry. The industry median Gross Margin % is 48.54. Allied Biotech's value of 37.32% is 23.1% below this benchmark. Historically, Allied Biotech's own Gross Margin % has ranged from 32.02 to 42.91 over the past decade. While the company's 10-year median is 37.98 vs. the industry median of 48.54, Allied Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allied Biotech's current Gross Margin % of 37.32% is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Allied Biotech and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied Biotech's current Gross Margin % is 37.32%, which is near median its own 10-year median of 37.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.77, compared to a current price of NT$22.30 — trading 7.4% above its estimated fair value. The current Gross Margin % is 37.32%, which is near median its 10-year median of 37.98 and 23.1% below the Drug Manufacturers industry median of 48.54. Allied Biotech's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current Gross Margin % is 37.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allied Biotech (ROCO:1780) Overvalued in 2026?
Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued.
The current stock price of NT$22.30 is trading 7.4% above its estimated GF Value™ of NT$20.77.
GuruFocus considers Allied Biotech to be Fairly Valued.
Key valuation signals for ROCO:1780:
Gross Margin %: 37.32% (near median its 10-year median of 37.98)
GF Value™: NT$20.77 vs. price of NT$22.30 (7.4% above fair value)
Industry Position: 23.1% below the Drug Manufacturers median (#671 of 942)
No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
77GF Score
Get the complete analysis for ROCO:1780
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1780 has been successfully added to your 
